Royce & Associates LP reduced its stake in PharMerica Co. (NYSE:PMC) by 91.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 38,412 shares of the company’s stock after selling 388,188 shares during the period. Royce & Associates LP owned approximately 0.12% of PharMerica worth $1,125,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. The Manufacturers Life Insurance Company raised its stake in shares of PharMerica by 0.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,228 shares of the company’s stock worth $610,000 after acquiring an additional 71 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of PharMerica by 0.9% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,614 shares of the company’s stock worth $305,000 after acquiring an additional 100 shares during the period. Arizona State Retirement System increased its stake in shares of PharMerica by 1.2% in the second quarter. Arizona State Retirement System now owns 16,216 shares of the company’s stock worth $426,000 after acquiring an additional 200 shares during the period. Texas Permanent School Fund boosted its holdings in PharMerica by 1.8% during the second quarter. Texas Permanent School Fund now owns 22,703 shares of the company’s stock worth $596,000 after buying an additional 411 shares in the last quarter. Finally, Public Employees Retirement System of Ohio boosted its holdings in PharMerica by 10.5% during the second quarter. Public Employees Retirement System of Ohio now owns 5,028 shares of the company’s stock worth $132,000 after buying an additional 476 shares in the last quarter. Hedge funds and other institutional investors own 89.97% of the company’s stock.
In related news, CEO Gregory S. Weishar sold 521,089 shares of the business’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $29.25, for a total value of $15,241,853.25. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 534,089 shares of company stock worth $15,243,073 over the last quarter. Insiders own 5.04% of the company’s stock.
PharMerica (NYSE:PMC) last issued its quarterly earnings results on Thursday, November 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). The firm had revenue of $595.10 million during the quarter, compared to analysts’ expectations of $596.80 million. PharMerica had a return on equity of 10.94% and a net margin of 0.83%. equities research analysts anticipate that PharMerica Co. will post 1.92 EPS for the current year.
Several equities analysts have issued reports on PMC shares. Zacks Investment Research downgraded shares of PharMerica from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. ValuEngine raised shares of PharMerica from a “hold” rating to a “buy” rating in a report on Tuesday, October 31st. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. PharMerica presently has a consensus rating of “Hold” and an average price target of $30.50.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.com-unik.info/2017/12/23/royce-associates-lp-trims-holdings-in-pharmerica-co-pmc.html.
Want to see what other hedge funds are holding PMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PharMerica Co. (NYSE:PMC).
What are top analysts saying about PharMerica? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PharMerica and related companies.